Table 2 Treatment patterns by region and country
|  | All Mosaic cohort | LA | Non-LA countries | p | Argentina | Brazil | México | p |
|---|---|---|---|---|---|---|---|---|
Freq of insulin injections/day mean | 1.63 (0.68) | 1.80 (0.68) | 1.60 (0.67) | <0.0001 | 1.99 (0.76) | 1.73 (0.73) | 1.69 (0.54) | <0.0001 |
Insulin regimen | ||||||||
 Basal insulin only | ||||||||
  Overall, n (%) | 2168 (49.9 %) | 365 (70.1 %) | 1803 (47.2 %) | <0.0001 | 103 (64.4 %) | 116 (74.8 %) | 146 (70.9 %) | <0.0001 |
  Once, n (%) | 1656 (76.4 %) | 152 (41.6 %) | 1504 (83.4 %) | 37 (35.9 %) | 52 (44.8 %) | 63 (43.2 %) | ||
  More than once, n (%) | 512 (23.6 %) | 213 (58.4 %) | 299 (16.6 %) | 66 (64.1 %) | 64 (55.2 %) | 83 (56.8 %) | ||
 Mixed insulin only |  | |||||||
  Overall, n (%) | 1284 (29.6 %) | 70 (13.4 %) | 1214 (31.8 %) | 36 (22.5 %) | 0 (0.0 %) | 34 (16.5 %) | ||
  Once, n (%) | 112 (8.7 %) | 4 (5.7 %) | 108 (8.9 %) | 1 (2.8 %) | 0 (0.0 %) | 3 (8.8 %) | ||
  More than once, n (%) | 1172 (91.3 %) | 66 (94.3 %) | 1106 (91.1 %) | 35 (97.2 %) | 0 (0.0 %) | 31 (91.2 %) | ||
 Short acting only |  | |||||||
  Overall, n (%) | 170 (3.9 %) | 11 (2.1 %) | 159 (4.2 %) | 1 (0.6 %) | 1 (0.6 %) | 9 (4.4 %) | ||
  Once, n (%) | 37 (21.8 %) | 2 (18.2 %) | 35 (22.0 %) | 1 (100.0 %) | 0 (0.0 %) | 1 (11.1 %) | ||
  More than once, n (%) | 133 (78.2 %) | 9 (81.8 %) | 124 (78.0 %) | 0 (0.0 %) | 1 (100.0 %) | 8 (88.9 %) | ||
 Other insulin combinations |  | |||||||
  Overall, n (%) | 597 (13.8 %) | 64 (12.3 %) | 533 (14.0 %) | 20 (12.5 %) | 27 (17.4 %) | 17 (8.3 %) | ||
  Once, n (%) | 172 (28.8 %) | 14 (21.9 %) | 158 (29.6 %) | 2 (10.0 %) | 9 (33.3 %) | 3 (17.6 %) | ||
  More than once, n (%) | 425 (71.2 %) | 50 (78.1 %) | 375 (70.4) | 18 (90.0 %) | 18 (66.7 %) | 14 (82.4 %) | ||
Other antidiabetic medication | ||||||||
 No. of OADs, mean (SD) | 1.22 (1.09) | 0.84 (0.88) | 1.27 (1.10) | <0.0001 | 0.66 (0.68) | 1.33 (0.91) | 0.61 (0.84) | <0.0001 |
 Metformin, n (%) | 2437 (56.1 %) | 280 (53.7 %) | 2157 (56.5 %) | 0.2400 | 82 (51.3 %) | 122 (78.7 %) | 76 (36.9 %) | <0.0001 |
 Sulfonylurea, n (%) | 1389 (32.0 %) | 92 (17.7 %) | 1297 (34.0 %) | <0.0001 | 13 (8.1 %) | 55 (35.5 %) | 24 (11.7 %) | <0.0001 |
 Dipeptidyl peptidase-4 inhibitor, n (%) | 538 (12.4 %) | 38 (7.3 %) | 500 (13.1 %) | 0.0002 | 2 (1.3 %) | 20 (12.9 %) | 16 (7.8 %) | 0.0003 |
 Alpha-glucosidase inhibitor, n (%) | 321 (7.4 %) | 7 (1.3 %) | 314 (8.2 %) | <0.0001 | 1 (0.6 %) | 2 (1.3 %) | 4 (1.9 %) | 0.5536 |
 GLP-1, n (%) | 143 (3.3 %) | 5 (1.0 %) | 138 (3.6 %) | 0.0015 | 2 (1.3 %) | 2 (1.3 %) | 1 (0.5 %) | 0.6678 |
 Other drug, n (%) | 443 (10.2 %) | 14 (2.7 %) | 429 (11.2 %) | <0.0001 | 5 (3.1 %) | 5 (3.2 %) | 4 (1.9 %) | 0.6952 |